Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial

Heart Rhythm

Volumn 14, Issue 9, 2017, Pages 1302-1308

  Boersma, Lucas V ^a   Ince, Hueseyin ^b   Kische, Stephan ^c   Pokushalov, Evgeny ^d   Schmitz, Thomas ^e   Schmidt, Boris ^f   Gori, Tommaso ^g   Meincke, Felix ^h   Protopopov, Alexey Vladimir ⁱ   Betts, Timothy ^j   Foley, David ^k   Sievert, Horst ^l   Mazzone, Patrizio ^m   De Potter, Tom ⁿ   Vireca, Elisa ^o   Stein, Kenneth ^p   Bergmann, Martin W ^q  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Vivantes Klinikum   (Germany)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

^e ELISABETH KRANKENHAUS ESSEN   (Germany)

^f CARDIOANGIOLOGISCHES CENTRUM BETHANIEN   (Germany)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h DEPARTMENT OF CARDIOLOGY   (Germany)

ⁱ Regional State Hospital   (Russian Federation)

^j OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^k BEAUMONT HOSPITAL   (Ireland)

^l CardioVascular Center Frankfurt   (Germany)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ OLV HOSPITAL   (Belgium)

^o Boston Scientific Neuromodulation   (Belgium)

^p Boston Scientific   (United States)

^q Cardiologicum Hamburg   (Germany)

more..

Author keywords

Atrial fibrillation; Bleeding; LAA closure; Left atrial appendage; Stroke

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CHA2DS2-VASC SCORE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; COHORT ANALYSIS; DEVICE EMBOLIZATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL MORTALITY; THROMBUS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG CONTRAINDICATION; EPIDEMIOLOGY; EUROPE; HEART ATRIUM APPENDAGE; INCIDENCE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CAUSE OF DEATH; CONTRAINDICATIONS, DRUG; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 85027866146     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2017.05.038     Document Type: Article

References (20)

1. Blackshear, J.L., Odell, J.A., Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 61 (1996), 755–759.
2. Reddy, V., Sievert, H., Halperin, J., Doshi, S.K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., Gordon, N., Holmes, D., PROTECT AF Steering Committee and Investigators. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 312 (2014), 1988–1998.
3. Price, M., Reddy, V., Valderrabano, M., Halperin, J., Gibson, D., Gordon, N., Huber, K., Holmes, D., Bleeding outcomes after left atrial appendage closure compared with long-term warfarin: a pooled, patient-level analysis of the WATCHMAN randomized trial experience. JACC Cardiovasc Interv 8 (2015), 1925–1932.
4. Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
5. Boersma, L., Schmidt, B., Betts, T., Sievert, H., Tamburino, C., Teiger, E., Stein, K., Bergmann, M., EWOLUTION: design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheter Cardiovasc Interv 88 (2016), 460–465.
6. Boersma, L.V., Schmidt, B., Betts, T.R., Sievert, H., Tamburino, C., Teiger, E., Pokushalov, E., Kische, S., Schmitz, T., Stein, K.M., Bergmann, M.W., EWOLUTION Investigators. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. Eur Heart J 37 (2016), 2465–2474.
7. Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123 (2011), 2736–2747.
8. Tzikas, A., Holmes, D., Gafoor, S., et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention 12 (2016), 103–111.
9. Leon, M.B., Piazza, N., Nikolsky, E., et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 32 (2011), 205–217.
10. Friberg, L., Rosenqvist, M., Lip, G., Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 33 (2012), 1500–1510.
11. Lip, G.Y.H., Frison, L., Halperin, J.L., Lane, D.A., Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal REnal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 57 (2011), 173–180.
12. Holmes, D., Kar, S., Price, M., Whisenant, B., Sievert, H., Doshi, S., Huber, K., Reddy, V., Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 64 (2014), 1–12.
13. Tzikas, A., Gafoor, S., Meerkin, D., et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 11 (2016), 1170–1179.
14. Holmes, D.R. Jr., Doshi, S., Kar, S., et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol 65 (2015), 2614–2623.
15. Reddy, V., Price, M., Valderrabano, M., Sanchez, J., Doshi, S., Gordon, N., Holmes, D., TCT-26 long-term event rates for left atrial appendage closure with WATCHMAN: PROTECT AF 5 year and PREVAIL 3 year follow-up. J Am Coll Cardiol, 68, 2016, B11.
16. Hanzel, G., Berman, A., Almany, S., Hiber, K., Holmes, D., TCT-176 comparison of imputed placebo versus observed ischemic stroke rates in the Watchman trials represents a significant reduction in risk. J Am Coll Cardiol, 64, 2014, B52.
17. Sharma, D., Reddy, V.Y., Sandri, M., et al. Left atrial appendage closure in patients with contraindications to oral anticoagulation. J Am Coll Cardiol 67 (2016), 2190–2192.
18. Lempereur, M., Aminian, A., Freixa, X., Gafoor, S., Kefer, J., Tzikas, A., Legrand, V., Saw, J., Device-associated thrombus formation after left atrial appendage occlusion: a systematic review of events reported with the Watchman, the Amplatzer Cardiac Plug and the Amulet. Catheter Cardiovasc Interv, 2017 Feb 1 http://dx.doi.org/10.1002/ccd.26903 [Epub ahead of print], PMID: 28145040.
19. Chun, K.R., Bordignon, S., Urban, V., Perrotta, L., Dugo, D., Fürnkranz, A., Nowak, B., Schmidt, B., Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience. Heart Rhythm 10:12 (2013 Dec), 1792–1799.
20. Holmes, D., Reddy, V., Buchbinder, M., Stein, K., Elletson, M., Bergmann, M., Schmidt, B., Saw, J., The assessment of the Watchman device in patients unsuitable for oral anticoagulation (ASAP-TOO) trial. Am Heart J 189 (2017), 68–84.